A bioprosthetic heart valve prepared by copolymerization of 2-isocyanatoethyl methacrylate modified pericardium and functional monomer. (1st June 2022)

• Record Type: Journal Article
• Authors: Zheng, Cheng; Ding, Kailei; Huang, Xueyu; Yang, Li; Lei, Yang; Wang, Yunbing
• Is Part Of: Composites. Number 238(2022)
• Publication Date: 2022-06-01
• Subjects: Bioprosthetic heart valves -- Glutaraldehyde-free crosslinking -- Biocompatibility -- Antithrombotic property -- Anticalcification -- Hydrodynamic performance and durability; Composite materials -- Periodicals; Materials science -- Periodicals; Composite materials; Periodicals; Electronic journals; 620.118
• DOI: 10.1016/j.compositesb.2022.109922
• Languages: English
• ISSNs: 1359-8368

Abstract

Abstract: Bioprosthetic heart valves (BHVs), mostly fabricated from glutaraldehyde crosslinked porcine or bovine pericardium, have been increasingly used in clinic with the application of transcatheter aortic valve replacement surgery. However, several drawbacks of glutaraldehyde crosslinked BHVs including poor cytocompatibility, thrombosis and calcification might lead to dysfunction and structural valvular degeneration (SVD) of BHVs. Here, we developed a glutaraldehyde-free crosslinking method in which the porcine pericardium was treated with 2-isocyanatoethyl methacrylate (ICM) to introduce methacrylate groups and subsequently copolymerized with crosslinker, poly(ethylene glycol) dimethacrylate (PEGDA), to prepare a PEGDA polymer crosslinked porcine pericardium (PICM-PEGDA-PP). The PICM-PEGDA-PP exhibited improved cytocompatibility, stability, mechanical properties and anticalcification property compared with glutaraldehyde crosslinked porcine pericardium (GA-PP). Owing to the introduction of PEGDA polymers, PICM-PEGDA-PP exhibited lower adsorption of proteins, platelets and blood cells as well as significant antithrombotic performance. Furthermore, the hydrodynamic performance and durability of PICM-PEGDA-PP were proved to meet the requirements of ISO 5840–3 for BHVs. These results indicated that the component stabilization and antithrombic functionalization of BHVs can be achieved by the proposed glutaraldehyde-free crosslinking method and PICM-PEGDA-PP is expected to be developed into a potential alternative for glutaraldehyde crosslinked BHVs clinically in the future. Graphical abstract: A poly(ethylene glycol) dimethacrylate (PEGDA) crosslinked BHV(PICM-PEGDA-PP) with antithrombosis, anticalcification and appropriate hydrodynamic performance and durability was prepared by the copolymerization of 2-Isocyanatoethyl methacrylate (ICM) modified porcine pericardium(ICM-PP) and crosslinker PEGDA. Image 1 Highlights: BHVs were prepared by copolymerization of ICM-PP and PEGDA monomer. The cytocompatibility and stability of PICM-PEGDA-PP were significantly improved. PICM-PEGDA-PP exhibited antithrombotic and anticalcification property. The hydrodynamic performance and durability of PICM-PEGDA-PP meet ISO 5840–3.